Edition:
United States

Sanofi SA (SNY)

SNY on New York Consolidated

38.09USD
30 Sep 2016
Change (% chg)

$0.26 (+0.69%)
Prev Close
$37.83
Open
$37.88
Day's High
$38.15
Day's Low
$37.67
Volume
1,431,972
Avg. Vol
2,367,783
52-wk High
$51.88
52-wk Low
$37.41

SNY

Chart for SNY

About

Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production... (more)

Overall

Beta: 0.97
Market Cap(Mil.): $98,339.80
Shares Outstanding(Mil.): 2,578.08
Dividend: 1.66
Yield (%): 4.40

Financials

  SNY Industry Sector
P/E (TTM): 21.22 36.90 36.83
EPS (TTM): 1.78 -- --
ROI: 4.96 14.48 13.93
ROE: 7.50 15.27 14.84

BRIEF-Sanofi appoints Alan Main to Executive Committee

* Sanofi appoints Alan Main to executive committee and executive vice president, consumer healthcare Source text for Eikon: Further company coverage: (Reporting By Dominique Vidalon)

9:04am EDT

Fitch Affirms L'Oreal SA at 'F1+'

(The following statement was released by the rating agency) MILAN/LONDON, September 27 (Fitch) Fitch Ratings has affirmed L'Oreal SA's (L'Oreal) Short-Term Issuer Default Rating (IDR) and commercial paper (CP) programme at 'F1+'. The agency has also affirmed L'Oreal USA Inc's CP programme, guaranteed by L'Oreal, at 'F1+'. The ratings continue to reflect the company's strong market position and product portfolio as well as its robust geographical diversification. Also, L'Oreal continues to d

Sep 27 2016

Sanofi gets $43 million U.S. funding to spur Zika vaccine development

Sanofi SA said on Monday the U.S. Department of Health and Human Services (HHS) approved $43.18 million in funding to accelerate the development of a Zika vaccine, as efforts to prevent the infection gather momentum.

Sep 27 2016

BRIEF-U.S BARDA grants $43.2 mln to Sanofi for Zika vaccine

* The United States Biomedical Advanced Research and Development Authority (BARDA) agrees to fund the manufacture of an inactivated Zika vaccine for phase II development by Sanofi and its vaccines global business unit Sanofi Pasteur

Sep 26 2016

Sanofi may win U.S. approval of $3 billion eczema drug by March

French drugmaker Sanofi  and its U.S. partner Regeneron Pharmaceuticals could win U.S. approval for their keenly awaited new eczema drug dupilumab, seen by analysts as a potential $3 billion-a-year seller, by next March.

Sep 26 2016

Sanofi may win U.S. approval of $3 bln eczema drug by March

Sept 26 French drugmaker Sanofi and its U.S. partner Regeneron Pharmaceuticals could win U.S. approval for their keenly awaited new eczema drug dupilumab, seen by analysts as a potential $3 billion-a-year seller, by next March.

Sep 26 2016

BRIEF-Sanofi and Regeneron accepted for priority review by U.S. FDA

* Sanofi and Regeneron announce dupilumab biologics license application accepted for priority review by U.S. FDA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Sep 26 2016

BRIEF-Sanofi files suit in U.S. to defend paten rights on Lantus and Lantus Solostar

* Files suit in U.S. To defend paten rights on Lantus and Lantus Solostar

Sep 19 2016

New Mexico AG sues Bristol-Myers, Sanofi over blood thinner

New Mexico Attorney General Hector Balderas has sued Bristol-Myers Squibb Co and Sanofi SA's U.S. arm for overstating the effectiveness of and concealing the risks of their blood thinner Plavix.

Sep 16 2016

UPDATE 2-Teva, Intel to develop wearable tech for Huntington's disease

Sept 15 Teva Pharmaceutical Industries Ltd said on Thursday it was collaborating with Intel Corp to develop a wearable technology platform to track the progression of disease in patients with Huntington's, a fatal degenerative disorder.

Sep 15 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : Wright Reports
$75.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00
Provider : Finlabo SIM Spa
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.